Early prediction of sustained viral responder and non-responder during interferon and ribavirin combination therapy in chronic hepatitis C
スポンサーリンク
概要
- 論文の詳細を見る
- 2005-12-01
著者
関連論文
- Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K_2
- New chemotherapy for patients with advanced hepatocellular carcinoma : Pilot study of β-interferon and doxorubicin one-shot intra-arterial chemotherapy
- Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene
- Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C
- Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor
- Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor
- Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines
- Hemochromatosis with Mutation of the Ferroportin 1 (IREG1) Gene
- Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells
- Hepatoma-derived growth factor is induced in liver regeneration
- Early prediction of sustained viral responder and non-responder during interferon and ribavirin combination therapy in chronic hepatitis C